Drug Type Biosimilar, Monoclonal antibody |
Synonyms Pembrolizumab Biosimilar (Celltrion, Inc.), CT-P51, CTP51 |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Lung Cancer | Phase 3 | Georgia | 30 Jan 2025 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | Georgia | 30 Jan 2025 | |
Lung Cancer | IND Application | United States | 24 Jun 2024 | |
Melanoma | IND Application | United States | 24 Jun 2024 | |
Stomach Cancer | IND Application | United States | 24 Jun 2024 |